Recruiting NA INTERVENTIONAL 2-arm NCT06654596

Efficacy and Safety of Telitacicept in IgAN

A Multicenter, Randomized, Controlled Clinical Study on the Efficacy and Safety of Telitacicept in Patients with IgA Nephropathy

Sponsor: Huashan Hospital

Conditions Glucocorticoid IgA Nephropathy (IgAN) Kidney Diseases Telitacicept

Interventions Glucocorticoid Telitacicept 240mg

Updated 3 times since 2024 Last updated: Dec 30, 2024 Started: Dec 6, 2024 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06654596, this NA trial focuses on Glucocorticoid and IgA Nephropathy (IgAN) and remains actively recruiting participants. Sponsored by Huashan Hospital, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Apr 2025 — Present [monthly]

Recruiting NA
Feb 2025 — Apr 2025 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Nov 2024 — Feb 2025 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Huashan Hospital
RenJi Hospital
Renmin Hospital of Wuhan University
Ruijin Hospital
Shanghai 6th People's Hospital
Shanghai Changzheng Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Longhua Hospital
Sichuan Provincial People's Hospital
Songjiang Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Wannan Medical College Yijishan Hospital
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China